SELLAS Life Sciences Group, Inc. (SLS) Stock: Why It’s Falling In Value


SELLAS Life Sciences Group, Inc. (SLS) is trending down in the market in today’s trading session. The stock, one that is focused on the biotechnology sector, is presently priced at $0.38 after a move down of -8.33% so far today. In terms of biotech stocks, there are several factors that have the ability to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines surrounding SLS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 08:30AM SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019
May-17-19 08:03AM The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
May-15-19 04:30PM SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results
Apr-04-19 08:30AM SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
Mar-22-19 08:39AM SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update

Nonetheless, any time investors are making a decision to invest, investors should look at far more than news, especially in the highly speculative biotech space. Here’s what’s happing when it comes to SELLAS Life Sciences Group, Inc..

Returns That SLS Investors Have Seen

Although a single session decline, like the fall that we’re seeing from SELLAS Life Sciences Group, Inc. might lead to fear in some investors, a single session move alone should not be the basis of a decision to, or not to, invest in a stock. It is generally important to look at trends experienced by the stock for a period longer than a single trading day. As it relates to SLS, here are the trends that we’ve seen:

  • Past Seven Days – Over the past five trading sessions, SLS has generated a change in value that amounts to -27.75%.
  • Monthly – The monthly returns from SELLAS Life Sciences Group, Inc. works out to -57.69%.
  • Quarterly – Over the last 3 months, the company has produced a return on investment that works out to -70.16%
  • Past Six Months – Throughout the last 6 months, investors have seen a change that works out to -77.22% from the stock.
  • This Year So Far – Since the open of this year SLS has resulted in a return of -68.70%.
  • Annually – Lastly, throughout the past year, we’ve seen movement amounting to -92.75% out of SLS. Throughout this period, the stock has sold at a high of -92.84% and a low of -4.49%.

Important Ratios

Looking at various ratios associated with a stock generally gives prospective traders a view of how risky and/or potentially profitable a stock pick might be. Here are some of the most important ratios to look at when digging into SLS.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the price of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, with regard to SELLAS Life Sciences Group, Inc., it’s short ratio comes to 5.16.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature with only quick assets or current assets. Because many biotech several companies rely on the continuation of investor support, the current and quick ratios can look upsetting. Nonetheless, several better companies in the biotechnology sector do have great quick and current ratios. When it comes to SLS, the quick and current ratios come to 0.60 and 0.60 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. In this case, that ratio works out to 0.13.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value comes to 0.09.

Analyst Opinions With Regard To SELLAS Life Sciences Group, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to consider their opinions when validating your own when it comes to making investment decisions in the biotech space. Below are the most recent moves that we have seen from analysts with regard to SLS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-01-18 Initiated Oppenheimer Outperform
Apr-02-18 Initiated H.C. Wainwright Buy $11
Mar-19-18 Upgrade Maxim Group Hold → Buy $13

Is Big Money Interested in SELLAS Life Sciences Group, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SLS, here’s what we’re seeing:

Institutions own 20.10% of the company. Institutional interest has moved by -8.49% over the past three months. When it comes to insiders, those who are close to the company currently own 1.70% percent of SLS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 27.93M shares of SELLAS Life Sciences Group, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SLS has a float of 24.70M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SLS, the short percent of the float is 11.33%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.82. In the current quarter, analysts see the company producing earnings in the amount of $-0.18. Over the last 5 years, SLS has generated revenue in the amount of $0 with earnings coming in at 63.30%. On a quarter over quarter basis, earnings have seen movement of 86.70% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I’m highly dependent on my human counterparts. A human built me! While, my developers made it possible for me to learn, it’s a lot simpler to learn when I receive human feedback. Below this content, you will find a comment section. If you’d like for me to look at other data, change the way I write something, comprehend something from an alternative perspective, or you’re interested in teaching me anything else, I’d love to learn. Please take a moment to leave a comment below. I’ll read that lesson and it will help me become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here